MedPath

Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Stage I Cancer of the Cervix

Phase 3
Terminated
Conditions
Cervical Cancer
Registration Number
NCT00054067
Lead Sponsor
Gynecologic Oncology Group
Brief Summary

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of radiation therapy combined with chemotherapy, with or without surgery, is more effective in treating early cancer of the cervix.

PURPOSE: Randomized phase III trial to compare the effectiveness of surgery followed by different regimens of radiation therapy and chemotherapy with that of chemotherapy and radiation therapy alone in treating patients who have stage I cancer of the cervix.

Detailed Description

OBJECTIVES:

* Compare progression-free survival and survival of patients with stage IB2 carcinoma of the cervix after radical hysterectomy with tailored chemoradiotherapy vs primary chemoradiotherapy.

* Compare the toxicity of these regimens in these patients.

* Compare the health-related quality of life of patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment arms.

* Arm I: (Surgery followed by chemoradiotherapy): Patients undergo exploratory laparotomy followed by radical hysterectomy and bilateral pelvic and para-aortic lymphadenectomy. Depending on the findings at surgery, the radical hysterectomy and lymphadenectomy are either completed or aborted.

* Aborted hysterectomy: Patients with aborted hysterectomy are assigned to 1 of 3 groups, depending on the findings at surgery.

* Group 1: Within 4 weeks of surgery, patients undergo pelvic radiotherapy 5 times weekly for 4-6 weeks and intracavitary irradiation during or after external radiotherapy. Patients also receive concurrent cisplatin IV over 1 hour once weekly for a total of 5-6 doses.

* Group 2: Patients receive radiotherapy and cisplatin as in group 1 with additional extended field radiotherapy.

* Group 3: Patients receive further treatment at the discretion of the investigator.

* Completed hysterectomy: Patients completing the radical hysterectomy are assigned to 1 of 3 groups, depending on the findings at surgery.

* Group A: Patients receive treatment as in group 1 above without intracavity irradiation.

* Group B: Patients receive treatment as in group 2 above without intracavity irradiation.

* Group C: Patients receive no further treatment.

* Arm II (Primary chemoradiotherapy): Patients undergo pelvic radiotherapy 5 times weekly for 4-6 weeks and intracavity irradiation during or after external radiotherapy. Patients also receive concurrent cisplatin IV over 1 hour once weekly for a total of 6 doses.

Quality of life is assessed at baseline, during week 5 of therapy, and then at 3, 6, and 12 months.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 740 patients (370 per treatment arm) will be accrued for this study within 7.5 years.

Recruitment & Eligibility

Status
TERMINATED
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (50)

Jonsson Comprehensive Cancer Center, UCLA

πŸ‡ΊπŸ‡Έ

Los Angeles, California, United States

University of Chicago Cancer Research Center

πŸ‡ΊπŸ‡Έ

Chicago, Illinois, United States

Ireland Cancer Center

πŸ‡ΊπŸ‡Έ

Cleveland, Ohio, United States

Abramson Cancer Center at University of Pennsylvania Medical Center

πŸ‡ΊπŸ‡Έ

Philadelphia, Pennsylvania, United States

Kagoshima City Hospital

πŸ‡―πŸ‡΅

Kagoshima City, Japan

CCOP - Christiana Care Health Services

πŸ‡ΊπŸ‡Έ

Newark, Delaware, United States

Walter Reed Army Medical Center

πŸ‡ΊπŸ‡Έ

Washington, District of Columbia, United States

CCOP - Grand Rapids

πŸ‡ΊπŸ‡Έ

Grand Rapids, Michigan, United States

Charles M. Barrett Cancer Center at University Hospital

πŸ‡ΊπŸ‡Έ

Cincinnati, Ohio, United States

Duke Comprehensive Cancer Center

πŸ‡ΊπŸ‡Έ

Durham, North Carolina, United States

Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center

πŸ‡ΊπŸ‡Έ

Nashville, Tennessee, United States

CCOP - Carle Cancer Center

πŸ‡ΊπŸ‡Έ

Urbana, Illinois, United States

Holden Comprehensive Cancer Center at University of Iowa

πŸ‡ΊπŸ‡Έ

Iowa City, Iowa, United States

Memorial Sloan-Kettering Cancer Center

πŸ‡ΊπŸ‡Έ

New York, New York, United States

Ellis Fischel Cancer Center at University of Missouri - Columbia

πŸ‡ΊπŸ‡Έ

Columbia, Missouri, United States

Abington Memorial Hospital

πŸ‡ΊπŸ‡Έ

Abington, Pennsylvania, United States

Kimmel Cancer Center at Thomas Jefferson University - Philadelphia

πŸ‡ΊπŸ‡Έ

Philadelphia, Pennsylvania, United States

CCOP - Geisinger Clinic and Medical Center

πŸ‡ΊπŸ‡Έ

Danville, Pennsylvania, United States

CCOP - Metro-Minnesota

πŸ‡ΊπŸ‡Έ

Saint Louis Park, Minnesota, United States

University of Alabama at Birmingham Comprehensive Cancer Center

πŸ‡ΊπŸ‡Έ

Birmingham, Alabama, United States

CCOP - Western Regional, Arizona

πŸ‡ΊπŸ‡Έ

Phoenix, Arizona, United States

CCOP - Columbia River Oncology Program

πŸ‡ΊπŸ‡Έ

Portland, Oregon, United States

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support

πŸ‡ΊπŸ‡Έ

Bethesda, Maryland, United States

CCOP - Michigan Cancer Research Consortium

πŸ‡ΊπŸ‡Έ

Ann Arbor, Michigan, United States

CCOP - Missouri Valley Cancer Consortium

πŸ‡ΊπŸ‡Έ

Omaha, Nebraska, United States

Women's Cancer Center at Community Hospital of Los Gatos

πŸ‡ΊπŸ‡Έ

Los Gatos, California, United States

Chao Family Comprehensive Cancer Center at University of California Irvine Cancer Center

πŸ‡ΊπŸ‡Έ

Orange, California, United States

Rush-Presbyterian-St. Luke's Medical Center

πŸ‡ΊπŸ‡Έ

Chicago, Illinois, United States

MBCCOP - University of Illinois at Chicago

πŸ‡ΊπŸ‡Έ

Chicago, Illinois, United States

CCOP - Evanston

πŸ‡ΊπŸ‡Έ

Evanston, Illinois, United States

CCOP - Central Illinois

πŸ‡ΊπŸ‡Έ

Decatur, Illinois, United States

Saint Joseph Regional Medical Center

πŸ‡ΊπŸ‡Έ

South Bend, Indiana, United States

Indiana University Cancer Center

πŸ‡ΊπŸ‡Έ

Indianapolis, Indiana, United States

University of Mississippi Medical Center

πŸ‡ΊπŸ‡Έ

Jackson, Mississippi, United States

CCOP - Kalamazoo

πŸ‡ΊπŸ‡Έ

Kalamazoo, Michigan, United States

CCOP - Cancer Research for the Ozarks

πŸ‡ΊπŸ‡Έ

Springfield, Missouri, United States

Cooper University Hospital

πŸ‡ΊπŸ‡Έ

Camden, New Jersey, United States

Long Island Cancer Center at Stony Brook University Hospital

πŸ‡ΊπŸ‡Έ

Stony Brook, New York, United States

Arthur G. James Cancer Hospital - Ohio State University

πŸ‡ΊπŸ‡Έ

Columbus, Ohio, United States

Penn State Cancer Institute at Milton S. Hershey Medical Center

πŸ‡ΊπŸ‡Έ

Hershey, Pennsylvania, United States

Magee-Womens Hospital

πŸ‡ΊπŸ‡Έ

Pittsburgh, Pennsylvania, United States

Southeast Gynecologic Oncology Associates

πŸ‡ΊπŸ‡Έ

Knoxville, Tennessee, United States

University of Texas - MD Anderson Cancer Center

πŸ‡ΊπŸ‡Έ

Houston, Texas, United States

University of Texas Medical Branch

πŸ‡ΊπŸ‡Έ

Galveston, Texas, United States

CCOP - Scott and White Hospital

πŸ‡ΊπŸ‡Έ

Temple, Texas, United States

Fletcher Allen Health Care - Medical Center Campus

πŸ‡ΊπŸ‡Έ

Burlington, Vermont, United States

University of Wisconsin Comprehensive Cancer Center

πŸ‡ΊπŸ‡Έ

Madison, Wisconsin, United States

Yale Comprehensive Cancer Center

πŸ‡ΊπŸ‡Έ

New Haven, Connecticut, United States

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill

πŸ‡ΊπŸ‡Έ

Chapel Hill, North Carolina, United States

CCOP - Kansas City

πŸ‡ΊπŸ‡Έ

Kansas City, Missouri, United States

Β© Copyright 2025. All Rights Reserved by MedPath